125 related articles for article (PubMed ID: 10431686)
1. Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery.
Silecchia G; Guarino E; Sinibaldi-Vallebona P; Pierimarchi P; Restuccia A; Spaziani E; Bernard P; Tuthill C; Garaci E; Rasi G
Cancer Immunol Immunother; 1999 Jul; 48(4):172-8. PubMed ID: 10431686
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats.
Rasi G; Silecchia G; Sinibaldi-Vallebona P; Spaziani E; Pierimarchi P; Sivilia M; Tremiterra S; Garaci E
Int J Cancer; 1994 Jun; 57(5):701-5. PubMed ID: 8194879
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice.
Mastino A; Favalli C; Grelli S; Rasi G; Pica F; Goldstein AL; Garaci E
Int J Cancer; 1992 Feb; 50(3):493-9. PubMed ID: 1735618
[TBL] [Abstract][Full Text] [Related]
4. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial infusions of interleukin-2-based immunochemotherapy in the treatment of unresectable liver metastases from colorectal cancer.
Okuno K; Hirohata T; Nakamura K; Jinnai H; Shigeoka H; Koh K; Shindo K; Yasutomi M
Clin Ther; 1993; 15(4):672-83. PubMed ID: 8221817
[TBL] [Abstract][Full Text] [Related]
6. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes.
Sztein MB; Serrate SA
Int J Immunopharmacol; 1989; 11(7):789-800. PubMed ID: 2599716
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats.
Sinibaldi Vallebona P; Rasi G; Pierimarchi P; Bernard P; Guarino E; Guadagni F; Garaci E
Int J Cancer; 2004 May; 110(1):70-5. PubMed ID: 15054870
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.
Fu QG; Meng FD; Shen XD; Guo RX
World J Gastroenterol; 2002 Dec; 8(6):1019-22. PubMed ID: 12439917
[TBL] [Abstract][Full Text] [Related]
10. Thymosin alpha1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts.
Li CL; Zhang T; Saibara T; Nemoto Y; Ono M; Akisawa N; Iwasaki S; Maeda T; Onishi S
Int Immunopharmacol; 2002 Jan; 2(1):39-46. PubMed ID: 11789668
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.
Garaci E; Pica F; Mastino A; Palamara AT; Belardelli F; Favalli C
J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):7-17. PubMed ID: 8435433
[TBL] [Abstract][Full Text] [Related]
12. Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects.
Lopez M; Di Lauro L; Paoletti G; Santini S; Gandolfo GM; Vitelli G; Frasca AM; Ameglio F; Rasi G; Garaci E
Ann Oncol; 1995 Dec; 6(10):1011-7. PubMed ID: 8750154
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
[TBL] [Abstract][Full Text] [Related]
14. The use of growth factors to modulate the activities of antigen-specific CD8+ T cells in vitro.
Alenzi FQ; Alenazi FA; Al-Kaabi Y; Salem ML
J Med Life; 2011 Nov; 4(4):399-406. PubMed ID: 22514573
[TBL] [Abstract][Full Text] [Related]
15. Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.
Wu Y; Deng Z; Wang H; Ma W; Zhou C; Zhang S
BMC Immunol; 2016 Sep; 17(1):29. PubMed ID: 27645787
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hydrocortisone-treated aged mice.
Hadden JW; Saha A; Sosa M; Hadden EM
Int J Immunopharmacol; 1995 Oct; 17(10):821-8. PubMed ID: 8707447
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
[TBL] [Abstract][Full Text] [Related]
18. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.
Jia Z; Feng Z; Tian R; Wang Q; Wang L
Immunopharmacol Immunotoxicol; 2015; 37(4):388-92. PubMed ID: 26250523
[TBL] [Abstract][Full Text] [Related]
19. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays.
Umeda Y; Sakamoto A; Nakamura J; Ishitsuka H; Yagi Y
Cancer Immunol Immunother; 1983; 15(2):78-83. PubMed ID: 6553515
[TBL] [Abstract][Full Text] [Related]
20. Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases.
Okuno K; Ohnishi H; Nakajima I; Akabane Y; Kurooka K; Koh K; Shindo K; Yasutomi M
Surg Today; 1994; 24(1):80-4. PubMed ID: 8054783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
